Study summary · research use only
Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study enrolled 375 male patients suspected of prostate cancer to evaluate circulating Humanin and MOTS-c (mitochondrial-derived peptides), the long non-coding RNA GAS5, and exosomal microRNAs miR-21 and miR-103 as markers for distinguishing benign prostatic hyperplasia (BPH), precancerous lesions (PL), and prostate cancer (PCa). Using ROC, PCA, PLS-DA, and decision tree analyses, the abstract reports Humanin and GAS5 were significantly downregulated in PL and PCa compared with BPH, while exosomal miR-21 and miR-103 were upregulated in PCa; miR-21 distinguished BPH from PL with an AUC of 1.000 and PL from PCa with an AUC of 0.9932. MOTS-c was elevated in PL compared with BPH. A plasma-only model combining Humanin, GAS5, and MOTS-c reached 95% cross-validated classification accuracy across the groups.
Abstract
This study aimed to evaluate the diagnostic significance of circulating mitochondrial-derived peptides, Humanin and MOTS-c, the long non-coding RNA GAS5, and exosomal microRNAs miR-21 and miR-103 in stratifying prostate diseases, including benign prostatic hyperplasia (BPH), precancerous lesions (PL), and prostate cancer (PCa). These biomarkers were selected based on their established roles in cellular stress responses, apoptosis regulation, inflammation, and tumor progression. A cohort of 375 male patients suspected of prostate cancer were enrolled. Plasma and exosomal levels of Humanin, MOTS-c, GAS5, miR-21, and miR-103 were measured. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and decision tree models. Results showed significant downregulation of Humanin and GAS5 in both PL and PCa compared to BPH, supporting their role in early disease transition. Exosomal miR-21 and miR-103 were significantly upregulated in PCa, with miR-21 exhibiting outstanding discriminative power between BPH and PL (AUC = 1.000) and between PL and PCa (AUC = 0.9932). MOTS-c, a mitochondrial-derived peptide, displayed elevated levels in PL compared to BPH, suggesting its involvement in early malignant transformation. A plasma-only diagnostic model combining Humanin, GAS5, and MOTS-c reached 95% cross-validated classification accuracy across clinical groups. Combination of circulating Humanin, MOTS-c, GAS5, and exosomal miRNAs provides a promising non-invasive biomarker panel for risk stratification in prostate diseases. This integrated molecular approach may enhance diagnostic precision and guide personalized clinical decision-making in prostate cancer management.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.